Back to Search
Start Over
Acquired Amegakaryocytic Thrombocytopenic Purpura: A Review of Therapeutic Options.
- Source :
-
Hematology/oncology and stem cell therapy [Hematol Oncol Stem Cell Ther] 2023 Apr 04; Vol. 16 (3), pp. 291-302. Date of Electronic Publication: 2023 Apr 04. - Publication Year :
- 2023
-
Abstract
- Acquired amegakaryocytic thrombocytopenic purpura (AATP) is a rare bone marrow disorder characterized by either a marked decrease or a complete absence of megakaryocytes with the preservation of all other cell lines. To date, more than 60 cases of AATP have been reported in the literature. Due to the rarity of this disease, no standard treatment guidelines have been established, and therapy is based on a handful of case studies and expert opinions. Herein, we provide a comprehensive review of currently utilized therapeutic options for AATP.
- Subjects :
- Humans
Megakaryocytes
Purpura, Thrombocytopenic therapy
Bone Marrow Diseases
Subjects
Details
- Language :
- English
- ISSN :
- 2589-0646
- Volume :
- 16
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Hematology/oncology and stem cell therapy
- Publication Type :
- Academic Journal
- Accession number :
- 37023223
- Full Text :
- https://doi.org/10.56875/2589-0646.1063